시장보고서
상품코드
1182887

세계의 바이오시밀러 시장(2022-2028년) : COVID-19의 영향 분석, 제품별, 용도별, 지역별 - 업계 분석, 시장 규모, 시장 점유율, 예측

Biosimilars Market with COVID-19 Impact Analysis, By Product, By Application, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2022-2028

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 365 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 바이오시밀러 시장 규모는 2021년에 311억 760만 달러에 달하고, 2022-2028년 예측기간 중 16.9%의 CAGR로 확대될 것으로 예상됩니다.

세계의 바이오시밀러(Biosimilars) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인·억제요인 분석, 시장 기회, COVID-19의 영향, 부문별 시장 분석, 경쟁 상황, 주요 기업 개요 등 체계적인 정보를 제공하고 있습니다.

목차

제1장 바이오시밀러 시장 : 개요

제2장 주요 요약

  • 시장 내역
    • 제품별
    • 용도별
    • 국가별
    • 지역별
  • 경쟁 분석

제3장 바이오시밀러 시장 : 주요 동향

  • 시장 성장 촉진요인
    • 시장 성장 촉진요인의 영향 분석
  • 시장 성장 억제요인
    • 시장 성장 억제요인의 영향 분석
  • 시장 기회
  • 시장 향후 동향

제4장 바이오시밀러 : 업계 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 매핑
  • 규제 체계 분석

제5장 바이오시밀러 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 바이오시밀러 시장 : 상황

  • 시장 점유율 분석(2021년)
  • 주요 제조업체별 내역 데이터
    • 확립된 기업 분석
    • 신흥 기업 분석

제7장 바이오시밀러 시장 : 제품별

  • 개요

제8장 바이오시밀러 시장 : 용도별

  • 개요

제9장 바이오시밀러 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제10장 바이오시밀러 업계 : 주요 벤더 분석

  • 경쟁 대시보드
  • 기업 개요
    • Eli Lilly and Company
    • Pfizer Inc.
    • Celltrion Healthcare
    • Novartis AG
    • Viatris Inc.(Mylan)
    • Samsung Bioepis Co. Ltd
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd
    • Intas Pharmaceutical Ltd
    • Biocon Limited
    • LG Life Sciences(LG Chem)
    • Amgen Inc.
    • Dr. Reddy's Laboratories
    • Coherus Biosciences Inc.
    • Biocad

제11장 애널리스트의 종합적 전망

제12장 부록

KSM 23.01.25

REPORT HIGHLIGHT

Biosimilars Market size was valued at USD 31,107.6 Million in 2021, expanding at a CAGR of 16.9% from 2022 to 2028.

The drugs known as biosimilars are derived from live organisms, though they can be produced in a variety of methods and using relatively different materials. Biosimilars are fundamentally different from generic medicines due to the complexity and high expense of their development as well as their molecular size and structure.

Market Dynamics

The rising elderly population and the rising incidence of chronic diseases, coupled with the quicker regulatory approval procedure are supporting the biosimilar market growth. The cost of biosimilars is more than 20% lower than its branded counterparts. As a result, patients can obtain highly effective treatments while also saving money. When compared to innovative biologics, biosimilars have cheaper Expenses. Because research expenses are lower, biosimilars are less expensive.

Reduced-priced biosimilars frequently cause the costs of reference biologics to rise due to manufacturer pricing rivalry. In the upcoming years, demand for biosimilar medicines is likely to rise because of their high cost-to-benefit ratio. The growing use of these medications throughout the world could lower direct spending on biologics. To acquire a competitive edge in the development, production, or sale of their products, numerous pharmaceutical companies are pursuing strategic partnerships, collaborations, and acquisitions. The partnerships want to give patients access to high-quality, affordable medicines.

COVID-19 Analysis:

Pharmaceutical companies specializing in the development of biosimilars face a substantial challenge. Additionally, according to a study titled "Impact of COVID-19 on Cancer Care: A Global Collaborative Study" that was released in September 2020, almost 90% of cancer care facilities encountered difficulties providing standard cancer care due to a variety of factors, including preventive measures, a lack of personal protective equipment, and staff shortages brought on by COVID-19.

Segmentation Analysis:

The Global Biosimilars Market is segmented based on Product, Application, and Region.

Based on the product, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others. During the projection period, the oncology segment is likely to witness strong revenue CAGR growth. As they add competition to the drug development process, biosimilars have a number of potential advantages in the treatment of cancer. Patients who must pay for the original products benefit greatly from the use of biosimilars in terms of financial savings. The term "biologics" refers to a broad range of goods, including vaccines, hormones, anti-allergy drugs, and blood and blood components. Oncology holds a sizeable portion of the market due to the introduction of new chemical and biological carcinogens that are raising the incidence of cancer. As a result of advancements in medical technology, doctors may now successfully cure patients who were diagnosed at a later stage and return them to normalcy. Cancer, however, spreads throughout the body as it progresses, reducing the range of available treatments. The cost of treatment for many cancer patients is reduced by the use of biosimilars, making it more accessible and affordable.

Regionally, the Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to the presence of various emerging players in the region. The increasing geriatric population in Asia-Pacific is associated with a high healthcare expenditure burden, and the market segment demands cost-effective options (i.e. biosimilars), which can augment market development. An increasing number of cancer patients in this region and the lack of medical infrastructure especially for cancer patients are creating opportunities for private manufacturers.

Recent Development:

In May 2022, Amneal Pharmaceuticals, Inc. received approval from the US Food and Drug Administration ("FDA") for a Biologics License Application ("BLA") for pegfilgrastim-pbbk, a biosimilar to Neulasta. The product will be sold under the brand name FYLNETRA.

Key features of the study:

  • This proposed research study on the Biosimilars market provides market size (US$ Million), compound annual growth rate (CAGR %) and forecast estimation (2022-2028), considering 2021 as the base year
  • The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for the Biosimilars market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Biosimilars market
  • The impact of COVID-19 on the Biosimilars market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Biosimilars market post-COVID will also be covered.
  • To give the users of this report a comprehensive view of the Biosimilars market, we have also included a competitive landscape and key innovator analysis for the Biosimilars market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Biosimilars market.
  • In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
  • The global Biosimilars market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILARS MARKET KEY PLAYERS

  • Eli Lilly and Company
  • Pfizer Inc.
  • Celltrion Healthcare
  • Novartis AG
  • Viatris Inc. (Mylan)
  • Samsung Bioepis Co. Ltd
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Intas Pharmaceutical Ltd
  • Biocon Limited
  • LG Life Sciences (LG Chem)
  • Amgen Inc.
  • Dr. Reddy's Laboratories
  • Coherus Biosciences Inc.
  • Biocad

GLOBAL BIOSIMILARS MARKET, BY PRODUCT

  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins

GLOBAL BIOSIMILARS MARKET, BY APPLICATION

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others

GLOBAL BIOSIMILARS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

TABLE OF CONTENT

1. Biosimilars Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilars Market Snippet by Product
    • 2.1.2. Biosimilars Market Snippet by Application
    • 2.1.3. Biosimilars Market Snippet by Country
    • 2.1.4. Biosimilars Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilars Key Market Trends

  • 3.1. Biosimilars Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilars Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilars Market Opportunities
  • 3.4. Biosimilars Market Future Trends

4. Biosimilars Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilars Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Biosimilars Market Landscape

  • 6.1. Biosimilars Market Share Analysis, 2021
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilars Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2021 & 2028 (%)
    • 7.1.2. Recombinant Non-Glycosylated Proteins
    • 7.1.3. Recombinant Glycosylated Proteins

8. Biosimilars Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2021 & 2028 (%)
    • 8.1.2. Oncology
    • 8.1.3. Blood Disorders
    • 8.1.4. Growth Hormonal Deficiency
    • 8.1.5. Chronic and Autoimmune Disorders
    • 8.1.6. Others

9. Biosimilars Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2021 & 2028 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Biosimilars Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Biosimilars Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Biosimilars Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Biosimilars Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Biosimilars Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2017 - 2028 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2017 - 2028, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Product, 2017 - 2028 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2017 - 2028 (US$ Million)

10. Key Vendor Analysis- Biosimilars Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Eli Lilly and Company
    • 10.2.2. Pfizer Inc.
    • 10.2.3. Celltrion Healthcare
    • 10.2.4. Novartis AG
    • 10.2.5. Viatris Inc. (Mylan)
    • 10.2.6. Samsung Bioepis Co. Ltd
    • 10.2.7. Stada Arzneimittel AG
    • 10.2.8. Teva Pharmaceutical Industries Ltd
    • 10.2.9. Intas Pharmaceutical Ltd
    • 10.2.10. Biocon Limited
    • 10.2.11. LG Life Sciences (LG Chem)
    • 10.2.12. Amgen Inc.
    • 10.2.13. Dr. Reddy's Laboratories
    • 10.2.14. Coherus Biosciences Inc.
    • 10.2.15. Biocad

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제